Similar Search Results

The welfare impact of parallel imports : a structural approach applied to the German market for oral anti-diabetics

Duso, Tomaso; Herr, Annika; Suppliet, Moritz - In: Health economics 23 (2014) 9, pp. 1036-1057

Persistent link: https://www.econbiz.de/10011306421

The welfare impact of parallel imports : a structural approach applied to the German market for oral anti-diabetics

Duso, Tomaso; Herr, Annika; Suppliet, Moritz - 2014

We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...

Persistent link: https://www.econbiz.de/10010338113

The welfare impact of parallel imports : a structural approach applied to the German market for oral anti-diabetics

Duso, Tomaso; Herr, Annika; Suppliet, Moritz - 2014

Persistent link: https://www.econbiz.de/10010339071

Product innovation success based on cancer research in the pharmaceutical industry : co-publication networks and the effects of partners

McKelvey, Maureen D.; Rake, Bastian - In: Industry and innovation 23 (2016) 5, pp. 383-406

Persistent link: https://www.econbiz.de/10011523939

Reference pricing and cost-sharing : theory and evidence on German off-patent drugs ; conference paper

Herr, Annika; Stühmeier, Torben; Wenzel, Tobias - 2014

-patent pharmaceuticals. We present a theoretical model with price-sensitive and loyal consumers that shows that a decrease in the reference …

Persistent link: https://www.econbiz.de/10010489291

The welfare impact of parallel imports : a structural approach applied to the German market for oral antidiabetics ; conference paper

Duso, Tomaso; Herr, Annika; Suppliet, Moritz - 2014 - Preliminary version

We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 antidiabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...

Persistent link: https://www.econbiz.de/10010481411

Pharmaceutical prices: the impact of the launch strategy : an analysis of German data

Böhler, Yvonne-Beatrice; Lamping, Christian; Wichardt, … - 2019

pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear … regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers …

Persistent link: https://www.econbiz.de/10012103333

Parallel imports and manufacturer rebates : evidence from Germany

Birg, Laura - 2019

pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …

Persistent link: https://www.econbiz.de/10011949028

Is self-regulation sufficient? : case of the German transparency code

Buske, Kristin; Jentzsch, Stefan J.; Bechter, Clemens - In: Administrative Sciences : open access journal 6 (2016) 1/3, pp. 1-12

The German pharmaceutical industry is stepping ahead with its implementation of a new transparency disclosure code for cooperation between pharmaceutical companies and health care professionals (HCPs) and health care organisations (HCOs). In Germany, this transparency code ("Transparenzkodex")...

Persistent link: https://www.econbiz.de/10012015756

Pharmaceutical prices : the impact of the launch strategy - an analysis of German data

Böhler, Yvonne-Beatrice; Lamping, Christian; Wichardt, … - 2019 - This Version: September 24, 2019

Persistent link: https://www.econbiz.de/10012119750

1
2
3
4
5
6
7
8
9
10
Next
Last